Followers | 603 |
Posts | 29843 |
Boards Moderated | 1 |
Alias Born | 01/30/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, August 05, 2023 5:26:36 PM
There’s a few people who hold millions (apart from the ones I mentioned last night) and a very large number who hold several hundred thousand shares each.
None of them have even posted on StockTwits during the week until this morning!
The founder of this company also founded Moderna and we all know what that one did during lockdown! It peaked at $400 a share during lockdown. Saying that, I appreciate that the share structure of both companies has changed over their product life cycle. But still the potential is clearly there for a significant re-rating of the stock on FDA Approval.
Let’s remember folks the technology is a game changer. Any hospital that uses a five day test for Candida Auris might be subject to lawsuits after this test from T2 gets approved!
Here’s the thing about the test - more tests will be used than people who actually have infections because when people are admitted to hospital, they will run the test as part of the screening process.
One in three people that has a Candida Auris infection dies from it. I can’t help but think that a large part of the reason for that is because of the huge delay in getting the results of existing tests back.
The company also has other tests in development and I would not be surprised if those other tests also significantly shortened the time for results to come back.
When you develop a product like this for one type of infection I’m sure that the team immediately starts looking at the similarities between that virus and at what adaptations need to be made to create a reliable test targeting any number of other infections where speedy diagnosis is time critical.
Another thought, the company very possibly might go it alone and not team up with another because of the $79m grant that they will qualify for on getting FDA approval.
Just my two cents worth!
My post are my opinion only. You should do your own due diligence before investing in any stock or take professional advice. I am not an investment advisor. Kind Regards.
Recent TTOO News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/05/2024 04:15:05 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/25/2024 01:04:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:49:54 PM
- T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements • GlobeNewswire Inc. • 05/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 11:00:55 AM
- T2 Biosystems Announces Closing of $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/17/2024 08:05:00 PM
- T2 Biosystems Announces $8 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- T2 Biosystems Announces CRG’s Conversion from Preferred Stock to Common Stock • GlobeNewswire Inc. • 05/14/2024 09:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/14/2024 08:55:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:43:56 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/13/2024 11:21:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 10:19:50 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/07/2024 11:46:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:57:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:48:00 PM
- T2 Biosystems Announces Letter of Intent to Enter Strategic Partnership for Lyme Disease • GlobeNewswire Inc. • 05/07/2024 01:00:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 09:27:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:24:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 09:19:02 PM
- T2 Biosystems Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/06/2024 08:34:38 PM
- T2 Biosystems Announces Commercial Expansion Through Middle East Distributor • GlobeNewswire Inc. • 05/06/2024 08:34:16 PM
- T2 Biosystems Announces the Conversion of an Additional $15 Million of CRG Term Loan into Equity • GlobeNewswire Inc. • 05/06/2024 08:29:41 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/06/2024 11:48:38 AM
- T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024 • GlobeNewswire Inc. • 04/24/2024 01:00:00 PM
- T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity • GlobeNewswire Inc. • 04/11/2024 08:05:00 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM